A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis

Trial Profile

A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Secukinumab (Primary) ; Secukinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms FUTURE 1 ext
  • Sponsors Novartis
  • Most Recent Events

    • 17 Jun 2017 3-Year efficacy and safety results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 20 Jan 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 28 Jan 2014 New source identified and integrated, European Clinical Trials Database (EudraCT2013-001241-13).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top